AU2012340020A1 - Pharmaceutical preparations of human RPE cells and uses thereof - Google Patents

Pharmaceutical preparations of human RPE cells and uses thereof Download PDF

Info

Publication number
AU2012340020A1
AU2012340020A1 AU2012340020A AU2012340020A AU2012340020A1 AU 2012340020 A1 AU2012340020 A1 AU 2012340020A1 AU 2012340020 A AU2012340020 A AU 2012340020A AU 2012340020 A AU2012340020 A AU 2012340020A AU 2012340020 A1 AU2012340020 A1 AU 2012340020A1
Authority
AU
Australia
Prior art keywords
cells
cell
rpe
rpe cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012340020A
Other languages
English (en)
Inventor
Roger GAY
Irina Klimanskaya
Robert Lanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012340020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Publication of AU2012340020A1 publication Critical patent/AU2012340020A1/en
Assigned to ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE reassignment ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE Alteration of Name(s) of Applicant(s) under S113 Assignors: ADVANCED CELL TECHNOLOGY, INC.
Priority to AU2017225146A priority Critical patent/AU2017225146C1/en
Priority to AU2019201201A priority patent/AU2019201201B2/en
Priority to AU2021204719A priority patent/AU2021204719B2/en
Priority to AU2025201277A priority patent/AU2025201277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AU2012340020A 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and uses thereof Abandoned AU2012340020A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2017225146A AU2017225146C1 (en) 2011-11-14 2017-09-08 Pharmaceutical preparations of human RPE cells and uses thereof
AU2019201201A AU2019201201B2 (en) 2011-11-14 2019-02-20 Pharmaceutical preparations of human RPE cells and uses thereof
AU2021204719A AU2021204719B2 (en) 2011-11-14 2021-07-06 Pharmaceutical preparations of human RPE cells and uses thereof
AU2025201277A AU2025201277A1 (en) 2011-11-14 2025-02-21 Pharmaceutical preparations of human RPE cells and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US61/559,521 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US61/589,741 2012-01-23
US201261724047P 2012-11-08 2012-11-08
US61/724,047 2012-11-08
PCT/US2012/065091 WO2013074681A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017225146A Division AU2017225146C1 (en) 2011-11-14 2017-09-08 Pharmaceutical preparations of human RPE cells and uses thereof

Publications (1)

Publication Number Publication Date
AU2012340020A1 true AU2012340020A1 (en) 2014-07-03

Family

ID=47470610

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012340020A Abandoned AU2012340020A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human RPE cells and uses thereof
AU2017225146A Active AU2017225146C1 (en) 2011-11-14 2017-09-08 Pharmaceutical preparations of human RPE cells and uses thereof
AU2019201201A Active AU2019201201B2 (en) 2011-11-14 2019-02-20 Pharmaceutical preparations of human RPE cells and uses thereof
AU2021204719A Active AU2021204719B2 (en) 2011-11-14 2021-07-06 Pharmaceutical preparations of human RPE cells and uses thereof
AU2025201277A Pending AU2025201277A1 (en) 2011-11-14 2025-02-21 Pharmaceutical preparations of human RPE cells and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2017225146A Active AU2017225146C1 (en) 2011-11-14 2017-09-08 Pharmaceutical preparations of human RPE cells and uses thereof
AU2019201201A Active AU2019201201B2 (en) 2011-11-14 2019-02-20 Pharmaceutical preparations of human RPE cells and uses thereof
AU2021204719A Active AU2021204719B2 (en) 2011-11-14 2021-07-06 Pharmaceutical preparations of human RPE cells and uses thereof
AU2025201277A Pending AU2025201277A1 (en) 2011-11-14 2025-02-21 Pharmaceutical preparations of human RPE cells and uses thereof

Country Status (23)

Country Link
US (4) US20130195806A1 (enExample)
EP (2) EP2780022B2 (enExample)
JP (7) JP6506023B2 (enExample)
KR (1) KR102054904B1 (enExample)
CN (2) CN113786417A (enExample)
AU (5) AU2012340020A1 (enExample)
CA (2) CA2855941A1 (enExample)
CY (1) CY1121819T1 (enExample)
DK (1) DK2780022T4 (enExample)
ES (1) ES2734453T3 (enExample)
FI (1) FI2780022T4 (enExample)
GB (1) GB2496969A (enExample)
HK (1) HK1202456A1 (enExample)
HR (1) HRP20191110T1 (enExample)
HU (1) HUE044778T2 (enExample)
IL (5) IL320536A (enExample)
LT (1) LT2780022T (enExample)
PL (1) PL2780022T3 (enExample)
PT (1) PT2780022T (enExample)
RS (1) RS59050B1 (enExample)
SI (1) SI2780022T1 (enExample)
TW (5) TWI785403B (enExample)
WO (1) WO2013074681A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2438815A3 (en) 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
KR101849336B1 (ko) 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
US20140227688A1 (en) 2011-09-26 2014-08-14 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US10676780B2 (en) 2011-09-26 2020-06-09 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
JP6506023B2 (ja) * 2011-11-14 2019-04-24 アステラス インスティテュート フォー リジェネレイティブ メディシン ヒトｒｐｅ細胞医薬品およびその使用
CN104755628B (zh) 2012-09-25 2019-03-01 凯杰有限公司 生物样品的稳定化
JP6426110B2 (ja) 2013-02-01 2018-11-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 人口多能性幹細胞（ｉｐｓｃ）由来の網膜色素上皮（ｒｐｅ）細胞を生成するための方法
CN105121643A (zh) 2013-03-18 2015-12-02 凯杰有限公司 细胞外核酸的稳定化和分离
EP2976424B1 (en) 2013-03-18 2018-10-03 Qiagen GmbH Stabilisation of biological samples
CN105814195A (zh) 2013-11-27 2016-07-27 京都府公立大学法人 层粘连蛋白应用于角膜内皮细胞培养
EP3080248A1 (en) 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CA2940692C (en) * 2014-03-18 2025-07-08 Qiagen Gmbh STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
WO2015175783A1 (en) * 2014-05-15 2015-11-19 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US11918630B2 (en) * 2014-10-31 2024-03-05 Kyoto Prefectural Public University Corporation Treatment of retina and nerve using laminin
WO2016067628A1 (ja) * 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる角膜の新規治療
US11865189B2 (en) 2014-12-18 2024-01-09 Sorbonne Universite Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
CN107406830A (zh) 2014-12-30 2017-11-28 细胞治疗神经科学有限公司 Rpe细胞群和制备它们的方法
BR112017014332A2 (pt) 2014-12-30 2018-01-02 Cell Cure Neurosciences Ltd métodos de tratamento de doenças retinianas
JP2018502575A (ja) 2014-12-30 2018-02-01 セル キュア ニューロサイエンシズ リミテッド 網膜色素上皮細胞集団の評価法
EP3274710B1 (en) * 2015-03-23 2021-06-09 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
DK3331994T3 (da) 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd Fremstilling af retinale pigmentepitelceller
JP7043392B2 (ja) 2015-08-18 2022-03-29 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
AU2016318774B2 (en) * 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
JP7166169B2 (ja) 2015-11-20 2022-11-07 キアゲン ゲーエムベーハー 細胞外核酸の滅菌のための滅菌組成物を調製する方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
EP3555266B1 (en) * 2016-12-13 2023-11-15 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
AU2018234933B2 (en) * 2017-03-16 2024-03-21 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
KR20200003110A (ko) * 2017-05-01 2020-01-08 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지 안구 병리학을 치료하기 위한 조성물 및 방법
AU2018393494A1 (en) * 2017-12-29 2020-07-09 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
WO2019164834A1 (en) 2018-02-22 2019-08-29 Ivantis, Inc. Ocular implant and delivery system
MX2020009152A (es) * 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3119041A1 (en) * 2018-11-19 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
CA3121177A1 (en) * 2018-12-05 2020-06-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vector for gene delivery
WO2020239714A1 (en) * 2019-05-28 2020-12-03 F. Hoffmann-La Roche Ag Method to generate monocytic progenitor cells
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3158763A1 (en) 2019-10-30 2021-05-06 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
US20230038379A1 (en) * 2019-11-22 2023-02-09 Sigilon Therapeutics, Inc. Monoclonal cell lines expressing an exogenous substance and uses thereof
CA3167649A1 (en) 2020-01-21 2021-07-29 Takeda Pharmaceutical Company Limited Compositions and methods of cryopreserving cells
CA3167195A1 (en) * 2020-02-07 2021-08-12 The Trustees Of Columbia University In The City Of New York Reprogramming the metabolome to delay onset or treat neurodegeneration
JPWO2022009969A1 (enExample) * 2020-07-10 2022-01-13
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
JPWO2023176906A1 (enExample) * 2022-03-16 2023-09-21
WO2024218311A1 (fr) * 2023-04-21 2024-10-24 Pulsesight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
CN121079095A (zh) * 2023-05-05 2025-12-05 加利福尼亚大学董事会 视网膜色素上皮细胞疗法
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
WO1999012572A1 (en) 1997-09-10 1999-03-18 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
WO1999034834A1 (en) * 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
JP2004535792A (ja) * 2001-04-27 2004-12-02 ザ ジェネラル ホスピタル コーポレーション チロシナーゼアッセイ法
ES2564553T3 (es) * 2001-08-08 2016-03-23 The Trustees Of The University Of Pennsylvania Procedimiento para purificar vectores víricos que tienen proteínas que se unen a ácido siálico
CA2468292A1 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2003060083A2 (en) 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2438815A3 (en) * 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
AU2005304978A1 (en) 2004-11-04 2006-05-18 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
KR101849336B1 (ko) * 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
AU2009236078B2 (en) * 2008-04-18 2014-03-06 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating age-related macular degeneration
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
EP2702135B1 (en) * 2011-04-29 2019-04-17 University of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
JP6506023B2 (ja) * 2011-11-14 2019-04-24 アステラス インスティテュート フォー リジェネレイティブ メディシン ヒトｒｐｅ細胞医薬品およびその使用
CN107148276A (zh) * 2014-09-05 2017-09-08 安斯泰来再生医药协会 视网膜神经节细胞及其祖细胞

Also Published As

Publication number Publication date
JP6563996B2 (ja) 2019-08-21
JP2021113193A (ja) 2021-08-05
EP2780022A4 (en) 2015-08-05
KR102054904B1 (ko) 2019-12-11
TWI842079B (zh) 2024-05-11
TW201828960A (zh) 2018-08-16
WO2013074681A9 (en) 2013-11-28
SI2780022T1 (sl) 2019-09-30
GB2496969A (en) 2013-05-29
JP6506023B2 (ja) 2019-04-24
TW202317157A (zh) 2023-05-01
IL287381B2 (en) 2024-04-01
IL320536A (en) 2025-06-01
JP7404441B2 (ja) 2023-12-25
CA2855941A1 (en) 2013-05-23
EP2780022A1 (en) 2014-09-24
IL287381B1 (en) 2023-12-01
US20130195806A1 (en) 2013-08-01
AU2019201201B2 (en) 2021-04-08
CA3178098A1 (en) 2013-05-23
DK2780022T4 (da) 2024-09-09
TWI655286B (zh) 2019-04-01
TW201333200A (zh) 2013-08-16
CN113786417A (zh) 2021-12-14
LT2780022T (lt) 2019-07-10
HUE044778T2 (hu) 2019-11-28
JP2022130370A (ja) 2022-09-06
JP2024037864A (ja) 2024-03-19
US20150366915A1 (en) 2015-12-24
IL308205B1 (en) 2025-06-01
RS59050B1 (sr) 2019-08-30
AU2019201201A1 (en) 2019-03-14
AU2017225146B2 (en) 2019-01-17
JP7081016B2 (ja) 2022-06-06
IL287381A (en) 2021-12-01
GB201220511D0 (en) 2012-12-26
KR20140096368A (ko) 2014-08-05
AU2021204719A1 (en) 2021-08-05
TWI785403B (zh) 2022-12-01
US20200405767A1 (en) 2020-12-31
US20250134932A1 (en) 2025-05-01
CY1121819T1 (el) 2020-07-31
JP2014533289A (ja) 2014-12-11
DK2780022T3 (da) 2019-07-15
HK1202456A1 (en) 2015-10-02
JP7716463B2 (ja) 2025-07-31
JP6899865B2 (ja) 2021-07-07
FI2780022T4 (fi) 2023-07-06
IL308205A (en) 2024-01-01
JP2019189614A (ja) 2019-10-31
AU2017225146C1 (en) 2019-08-22
IL232600B (en) 2020-03-31
IL232600A0 (en) 2014-06-30
CN104080464A (zh) 2014-10-01
IL273107A (en) 2020-04-30
EP3563860A1 (en) 2019-11-06
WO2013074681A1 (en) 2013-05-23
HRP20191110T1 (hr) 2019-09-20
TWI719277B (zh) 2021-02-21
JP2025161815A (ja) 2025-10-24
AU2025201277A1 (en) 2025-03-13
EP2780022B1 (en) 2019-06-05
IL273107B (en) 2021-12-01
AU2021204719B2 (en) 2024-11-21
EP2780022B2 (en) 2022-09-07
PT2780022T (pt) 2019-07-16
ES2734453T3 (es) 2019-12-10
PL2780022T3 (pl) 2019-11-29
IL308205B2 (en) 2025-10-01
JP2018048144A (ja) 2018-03-29
TW202120107A (zh) 2021-06-01
AU2017225146A1 (en) 2017-10-05
TW202434266A (zh) 2024-09-01

Similar Documents

Publication Publication Date Title
AU2021204719B2 (en) Pharmaceutical preparations of human RPE cells and uses thereof
HK40015631A (en) Pharmaceutical preparations of human rpe cells and uses thereof
HK40064545A (en) Pharmaceutical preparations of human rpe cells and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted